Compare SII & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | DYN |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2011 | 2020 |
| Metric | SII | DYN |
|---|---|---|
| Price | $104.49 | $23.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $132.00 | $37.00 |
| AVG Volume (30 Days) | 181.2K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.03 | N/A |
| Revenue Next Year | $11.83 | N/A |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.94 | $8.88 |
| 52 Week High | $169.63 | $25.00 |
| Indicator | SII | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 60.70 |
| Support Level | $103.64 | $16.47 |
| Resistance Level | $120.13 | $24.52 |
| Average True Range (ATR) | 3.97 | 1.40 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 15.75 | 63.43 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.